[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
Environmental Carcinogens |
|
|
Clinical Trial: Treating Thought Problems in Patients with Schizophrenia
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to compare Cognitive Adaptation Training (CAT) to minimal schizophrenia treatment. This study will also determine whether the intensity of CAT can be reduced and still provide benefits to patients with schizophrenia.
| Condition | Treatment or Intervention |
|---|---|
| Schizophrenia | Behavior: Cognitive Adaptation Therapy (CAT) Behavior: Minimal Environmental Supports (MES) |
MedlinePlus related topics: Schizophrenia
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Compensating for Cognitive Deficits in Schizophrenia
Expected Total Enrollment: 120
Study start: February 2002
Many schizophrenia patients have serious difficulties that affect their quality of life. Cognitive Adaptation Training (CAT) may improve adaptive functioning, quality of life, and rates of relapse in schizophrenia patients. CAT, which involves compensatory strategies or environmental supports, is tailored to each individual and is based on executive functioning levels and other factors.
Participants are randomly assigned to CAT, Minimal Environmental Supports (MES), or treatment as usual for 2 years. Participants receiving CAT will have a trained therapist make weekly visits to their home for 9 months. Over the following 3 months, the frequency of CAT visits will be slowly reduced to once a month. For the remaining 12 months of treatment, patients receive CAT only once a month.
Participants assigned to the MES group receive a generic set of supplies and equipment (calendar, alarm clock, watch, bus passes, etc.) at the beginning of the 2-year period. Each month, the supplies are replenished as necessary during the patient's scheduled clinic visit.
In all groups, assessments of adaptive function and quality of life occur at study start and at 3, 6, 9, 18, and 24 months.
Eligibility
Ages Eligible for Study: 18 Years - 60 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- DSM-IV diagnosis of schizophrenia or schizoaffective disorder
- Treatment with an atypical antipsychotic medication
- Stable living environment
- Able to read, understand, and complete rating scales and neuropsychological testing
- Willing to participate in psychosocial treatments for schizophrenia that may involve home visits
Exclusion Criteria:
- History of significant head trauma, seizure disorder, or mental retardation
- Alcohol or drug abuse that could interfere with participation in the study
- Treatment by an ACT team
- History of violence in the past year
- Score > 80 on the SOFAS
- Hospitalized in the past year
Location and Contact Information
Texas
University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States; Recruiting
Elladean Lopez, M.A. 210-531-8344 elladean.lopez@mhmr.state.tx.us
Dawn I. Velligan, Ph.D., Principal Investigator
Alexander L. Miller, M.D., Sub-Investigator
Thomas J. Prihoda, Ph.D., Sub-Investigator
Dawn I. Velligan, Ph.D., Principal Investigator, University of Texas
More Information
Record last reviewed: November 2004
Last Updated: November 10, 2004
Record first received: January 15, 2003
ClinicalTrials.gov Identifier: NCT00051740
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- A Place for Women (Cornell University)
- Air and Radiation: A Guide to the UV Index and Sun-Safe Behavior (Federal Citizen Information Center, GSA)

Not Signed In -


